Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
A major class action settlement related to proton pump inhibitors (PPIs) and dementia claims has raised significant concerns about the safety of these commonly used medications. However, it’s important to note that while there has substantial litigation around PPIs—including a $425 million settlement with AstraZeneca for kidney injuries—the specific $145 million dementia settlement referenced requires careful examination. Verified records show significant PPI litigation has focused primarily on kidney and related organ damage rather than neurological claims, though emerging research has created important connections between long-term PPI use and increased dementia risk that deserves attention from anyone taking these medications.
For millions of Americans taking proton pump inhibitors for acid reflux and heartburn, questions about long-term safety have become increasingly relevant. An important 2016 study published in JAMA Neurology found that people aged 75 and older using PPIs showed a 44% increased risk of developing dementia compared to those not using these medications. This research examined popular brands including Nexium, Prilosec, and Prevacid—medications that many people have taken for years without awareness of potential cognitive risks.
Table of Contents
- What Are Proton Pump Inhibitors and Why Are They So Widely Used?
- The Dementia Link: What the Research Actually Shows
- The Existing PPI Settlements and What They Cover
- Who Should Be Concerned and What This Means for Current Users
- Understanding the Litigation Landscape and Challenges
- What People Taking PPIs Should Monitor
- The Future of PPI Safety and Pharmaceutical Accountability
- Conclusion
What Are Proton Pump Inhibitors and Why Are They So Widely Used?
Proton pump inhibitors are a class of medications that reduce stomach acid production by blocking proton pumps in the stomach lining. They’re prescribed for conditions like gastroesophageal reflux disease (GERD), peptic ulcer disease, and Barrett’s esophagus. The appeal of these medications is clear: they work effectively at reducing acid-related symptoms, providing relief to millions of Americans who struggle with severe heartburn and acid reflux. Many people have taken them for decades without complications, making them among the most frequently prescribed medications in the United States.
The widespread use of PPIs has made them a fixture of modern medicine, with over 15 million americans using these drugs regularly. Some patients take them daily for years, occasionally even decades, under the assumption that extended use is safe because they’re available over-the-counter. However, the original intent of these medications was short-term use—typically 8 weeks or less—yet many patients continue using them far beyond that window. This gap between intended use and actual practice has become a growing concern for researchers and healthcare providers monitoring long-term health outcomes.
The Dementia Link: What the Research Actually Shows
The potential connection between PPIs and dementia emerged from careful observation and rigorous scientific research rather than manufacturer data. The landmark 2016 JAMA Neurology study examined electronic health records from Kaiser Permanente’s Northern California database, tracking over 73,000 individuals aged 75 and older. Among those who regularly used proton pump inhibitors, researchers documented a statistically significant 44% increase in dementia risk compared to non-users, even after adjusting for other known dementia risk factors. What makes this finding particularly concerning is that the increased risk appeared even among people with no prior dementia diagnosis at the start of the study.
The mechanism behind this connection isn’t fully understood, though researchers have proposed several theories: PPIs may interfere with the absorption of crucial nutrients like vitamin B12, magnesium, and calcium that protect brain health; they may alter the stomach bacteria composition in ways that affect brain function through the gut-brain axis; or they may trigger chronic inflammation affecting cognitive function. However, these remain hypotheses rather than proven mechanisms, meaning that while the correlation is real, the “why” remains an active area of research. A critical limitation of this research is that it shows correlation, not causation. Not everyone taking PPIs develops dementia, and many factors contribute to dementia risk including genetics, age, education level, cardiovascular health, and other medications. Additionally, the study focused specifically on older adults aged 75 and above, so the dementia risk for younger PPI users remains less clear from this particular research.
The Existing PPI Settlements and What They Cover
The major class action settlements involving proton pump inhibitors have focused on kidney injuries rather than dementia claims. AstraZeneca, the manufacturer of popular PPI brands Nexium and Prilosec, settled litigation for $425 million in cases covering approximately 11,000 plaintiffs who claimed the medication caused interstitial nephritis or chronic kidney disease. GlaxoSmithKline, Procter & Gamble, Pfizer, and Takeda Pharmaceuticals have also faced litigation, with total PPI-related settlements reaching $590.4 million across multiple defendants. These kidney-focused settlements reflect litigation that developed in the early 2010s as doctors began documenting cases of acute kidney injury in patients taking PPIs.
Some patients experienced rapid and severe loss of kidney function after months or years of regular PPI use, cases that created documented medical evidence and a clear pattern of harm. For those settlements, plaintiffs had medical records showing kidney function changes correlating with medication use, providing the kind of direct clinical evidence that supports class action certification. The absence of a verified $145 million dementia-specific settlement, despite the concerning research findings, highlights a critical gap in accountability. While the dementia research is compelling, translating it into successful litigation has proven more challenging because establishing direct causation in individual cases is more difficult, and the mechanism of harm remains incompletely understood compared to the kidney injury pathway.
Who Should Be Concerned and What This Means for Current Users
Anyone aged 75 or older taking a proton pump inhibitor should have a serious conversation with their healthcare provider about whether continued use is necessary. This recommendation is particularly important for those who’ve been taking PPIs for more than a few months, as the original clinical guidelines recommend limiting PPI use to 4-8 weeks for acute conditions, with longer-term use reserved for specific diagnoses like Barrett’s esophagus or chronic severe GERD where benefits clearly outweigh risks. The risk-benefit calculation looks different for different people. A 78-year-old who takes a PPI for occasional heartburn should likely discuss discontinuing it with their doctor.
By contrast, a 72-year-old with a documented pre-malignant condition (Barrett’s esophagus) where the PPI provides significant protection against progression to cancer faces a different tradeoff. For younger people in their 50s and 60s, the dementia data from the 75+ population may be less directly applicable, though the principle of using the lowest effective dose for the shortest possible duration remains sound medical practice. Importantly, stopping PPIs abruptly can cause a rebound increase in stomach acid, making gradual tapering under medical supervision the appropriate approach rather than simply discontinuing the medication. This means the conversation with your doctor shouldn’t be about whether to stop, but rather about whether continued use remains justified given the emerging safety data, and if discontinuation is appropriate, how to do so safely.
Understanding the Litigation Landscape and Challenges
The gap between the dementia research findings and successful litigation reflects fundamental challenges in establishing pharmaceutical liability. Courts and juries typically require clear evidence of causation linking a specific drug to a specific injury in the plaintiff’s case. With kidney injuries from PPIs, this causation chain is relatively straightforward: the patient took the medication, developed documented kidney dysfunction, and the temporal relationship is clear. With dementia, however, the causation becomes murkier because multiple factors contribute to dementia development over years or decades.
Additionally, pharmaceutical companies have argued that dementia risk in older adults is multifactorial, and that the PPI use is simply one of many contributing factors rather than the primary cause. Establishing that an individual’s dementia was “caused by” their PPI use rather than by aging, genetics, cardiovascular disease, or other conditions requires expert testimony and evidence that would be expensive and difficult to prove for each individual case. This legal and scientific burden is one reason why, despite the concerning research, we haven’t seen major dementia-related PPI settlements comparable to the kidney injury settlements. Another limitation is the timeframe: dementia typically develops over years or even decades, making it harder to establish the temporal relationship required in legal cases. Someone may have taken a PPI from age 50 to 70, stopped, and then developed dementia at 80—making it difficult to prove the PPI use years earlier directly caused the condition.
What People Taking PPIs Should Monitor
For anyone currently taking proton pump inhibitors, particularly those over 75 or those who’ve been on these medications long-term, paying attention to cognitive changes makes sense. While dementia develops gradually and the PPI-dementia link remains statistically significant but not inevitable, tracking memory, processing speed, and overall mental acuity provides baseline information. If someone notices meaningful cognitive decline, this should be discussed with their doctor in context of their medication list.
Equally important is monitoring nutritional status. PPIs reduce stomach acid, which is necessary for absorbing vitamin B12, magnesium, calcium, and other nutrients critical for brain health. For long-term PPI users, periodic blood work checking B12, magnesium, and calcium levels, followed by supplementation if needed, represents one practical approach to minimizing potential harm while continuing PPI use if it remains medically necessary.
The Future of PPI Safety and Pharmaceutical Accountability
As research continues on the mechanisms linking PPIs to dementia and other long-term health effects, the pharmaceutical and medical communities face pressure to update prescribing guidelines. Current guidance already recommends limiting PPI use to the shortest duration necessary, yet many patients remain on indefinite PPI therapy without regular reassessment.
Future litigation success on dementia claims may depend on establishing clearer causation mechanisms through ongoing research or identifying subgroups of patients at particular risk. The broader lesson from PPI settlements—both the kidney injury cases that have succeeded and the dementia cases that have been slower to materialize—is that medications approved for short-term use often continue indefinitely without adequate ongoing safety monitoring. As an aging population takes more medications for longer periods, this pattern will likely repeat with other drug classes, making it increasingly important for both patients and healthcare providers to regularly question whether long-standing medications remain necessary and safe.
Conclusion
While a specific $145 million settlement focused on proton pump inhibitors and dementia claims has not been verified through current legal databases, the underlying concern is absolutely legitimate. The research showing a 44% increased dementia risk in older adults taking PPIs is credible and peer-reviewed, and existing PPI litigation (including $590 million in settlements for kidney injuries) demonstrates that these medications carry real risks when used long-term.
For anyone taking a PPI—particularly those aged 75 and older or those on long-term therapy—a conversation with their healthcare provider about whether the medication remains necessary is a prudent step. The next important action is not to panic or abruptly stop a PPI if your doctor prescribed it for a valid reason, but rather to engage in informed discussion about risk-benefit calculations, proper dosing and duration, monitoring for cognitive changes, and nutritional status. As pharmaceutical safety research evolves, staying informed and maintaining regular healthcare provider communication about all medications—not just PPIs—becomes an essential part of maintaining both physical and cognitive health as we age.
You Might Also Like
- Class Action Lawsuit Filed Against Maker of Common Sleep Aid Over Dementia Claims
- Johnson and Johnson Settles $9 Billion Lawsuit Over Talc Linked to Dementia
- FDA Warns of Brain Bleeding Risk With New Class of Dementia Drugs
For more, see NIH MedlinePlus — dementia.
